Freeze variability, not progress: strengthen your cell therapy supply chain from the start

Episode 197

0:00-30:25

Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled. My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark. 01:07 Meet Dominic Clarke and Cryoport Systems 06:24 Fresh cells versus frozen cells 08:21 Why teams switch to cryopreservation late 12:37 The challenge of variability 16:47 IntegriCell when you already have a process in place 22:17 An argument for cryopreservation based on data 25:56 The future of IntegriCell and Cryoport Systems This episode is brought to you with the support of Cryoport Systems. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Publisher

Beyond Biotech - the podcast from Labiotech

Published

May 15, 2026

Duration

30 min

Format

Podcast

Category

Issues · Tech News

Source

RSS feed

Host

Labiotech

BB

Beyond Biotech - the podcast from Labiotech

@beyondbiotechthepodcastfroml

#freezevariability #strengthen #celltherapysupply

The Nile